A prospective study of incidence and outcome of acute kidney injury among hospitalised patients in Malaysia (My-AKI)

Ching Yan Goh, MRCP¹, Visvanathan Ravindran, FRCP², Chin Tho Leong, MB BAO BCh³, Lai Seong Hooi, FRCP⁵, Chin Chin Ch'ng, MPH³, Seow Yeing Yee, MRCP², Khairul Anuar Abdul Manaf, MMed⁶, Lily Mushahar, MMed⁷, Kheng Wee Goh, MRCP⁸, Yew Fong Liew, MMed⁴, Anita Manocha, FRCP⁹, Loke Meng Ong, FRCP^{3,4}

¹Department of Nephrology, Selayang Hospital, Malaysia, ²Department of Nephrology, Kuala Lumpur Hospital, Malaysia, ³Clinical Research Centre, Penang Hospital, Malaysia, ⁴Department of Medicine, Penang Hospital, Malaysia, ⁵Department of Medicine, Sultanah Aminah Hospital, Johor Bahru, Malaysia, ⁶Department of Nephrology, Tengku Ampuan Rahimah Hospital, Klang, Malaysia, ⁷Department of Nephrology, Tuanku Ja'afar Hospital, Seremban, Malaysia, ⁸Department of Nephrology, Serdang Hospital, Malaysia, ⁹Department of Medicine, Seberang Jaya Hospital, Malaysia

ABSTRACT

Introduction: The incidence of acute kidney injury (AKI) among hospitalised patients has not been well studied in Malaysia.

Materials and Methods: We conducted a prospective, multicentre study in seven hospitals in West Malaysia. All the adults admitted in March 2017 fulfilling Kidney Disease Improving Global Outcomes (KDIGO) criteria for AKI were included.

Results: Of the 34,204 patients screened, 2,457 developed AKI (7.18%), 13.1% of which occurred in intensive care unit (ICU). There were 60.2% males with a mean age of 57.8 (±17.5) years. The most common comorbidities were hypertension (55.0%), diabetes (46.6%), ischaemic heart disease (15.1%) and chronic kidney disease (12.0%). The commonest causes of AKI were sepsis (41.7%), pre-renal (24.2%) and cardiorenal syndrome (10.8%). Nephrotoxin exposure was reported in 31%. At diagnosis, the proportion of AKI stages 1, 2 and 3 were 79.1%, 9.7%, 11.2%, respectively. Referral to nephrologists was reported in 16.5%. Dialysis was required in 176 (7.2%) patients and 55.6% were performed in the ICU. Acidosis (46.2%), uraemia (31.6%) and electrolyte disturbance (11.1%) were the commonest indications. Continuous renal replacement therapy (CRRT) was required in 14%. The average length of hospital stay was 9.5 days. In-hospital mortality was 16.4%. Among survivors, full and partial renal recovery was seen in 74.7% and 16.4% respectively while 8.9% failed to recover. After a mean follow-up of 13.7 months, 593 (30.2%) of survivors died and 38 (1.9%) initiated chronic dialysis. Mortality was highest among those with malignancies (Hazard Ratio, HR 2.14), chronic liver disease (HR 2.13), neurological disease (HR 1.56) and cardiovascular disease (HR 1.17).

Conclusion: AKI is common in hospitalised patients and is with associated high mortality during and after hospitalisation.

KEYWORDS:

Acute kidney injury, prospective study, Malaysia

INTRODUCTION

Acute kidney injury (AKI) is a condition with rapid reduction in renal function. It is independently associated with morbidity, mortality, increased length of hospital stays, progression of chronic kidney disease (CKD), increased need for renal replacement therapy (RRT) and increased healthcare costs. The incidence varies from 5 to 20% of hospitalised patients in developed countries.

In Malaysia, the incidence of AKI among hospitalised patients has not been well studied. Single centre studies over the past few decades have shown increasing incidence of AKI among hospitalised patients.¹⁻³ The Malaysian Registry of Intensive Care in 2016 reported that 15.7% of the patients in intensive care unit (ICU) developed AKI within the first 24 hours of their admission.⁴

In the past there has been a lack of standardisation in defining AKI. Recently, consensus has been reached on the universal definition and staging of AKI after harmonising the previous definitions and staging systems to allow early detection and management of AKI.^{5,6} This will also enable future research on the incidence, aetiologies, risk factors, outcomes and efficacy of therapeutic interventions for AKI globally.

All hospitalised patients are at risk of AKI either through their presenting illness, complications or iatrogenic causes. The rising incidence of AKI in developed countries is largely driven by sepsis, dehydration or volume depletion, trauma and exposure to nephrotoxic drugs. It may also be related to aggressive medical and surgical therapies on an ageing population with multiple comorbidities. These patients are mostly admitted under the care of non-nephrology healthcare professionals, who may not be familiar with the early detection of AKI. Prevention and optimum care of AKI

This article was accepted: 16 September 2023 Corresponding Author: Loke Meng Ong Email: onglokemeng@gmail.com

in these patients may not be provided in a timely manner.⁷ In 2009, the National Confidential Enquiry into Patient Outcome and Death (NCEPOD) in the United Kingdom described systemic deficiencies in the care of patients who died from AKI and only 50% of them had received "good" care. Deficiencies included failure in AKI prevention, recognition, therapy and timely access to specialist services.⁸ Published series on AKI suggested that up to 30% of cases may be preventable, with a further significant percentage potentially remediable through simple interventions such as volume repletion, discontinuing and/or avoiding certain potentially nephrotoxic agents and earlier recognition of conditions causing rapid progression of AKI.⁹⁻¹¹ It is therefore, important to raise awareness of AKI and its prevention among healthcare professionals.

AKI in developing countries is commonly due to gastroenteritis or infections-related diseases such as malaria, leptospirosis and dengue. These are largely preventable and occur in young and healthy individuals.¹² Patients with AKI have a poorer prognosis with mortality ranging from 10 to 80% depending on the patient population.¹³⁻¹⁵ A total of 5 to11% of ICU patients will require renal replacement therapy (RRT) and long-term survival is poor.¹⁶⁻¹⁹ AKI is a risk factor for the development of chronic kidney disease (CKD), worsening of pre-existing CKD and may lead to end stage kidney disease (ESKD).²⁰⁻²²

The purpose of this study is to determine the incidence and evaluate the causes, risk factors and outcomes of AKI among hospitalised adult patients in Malaysia.

MATERIALS AND METHODS

This is a prospective, observational study designed to determine the incidence and outcomes of AKI in hospitalised patients (18 years and above) in seven hospitals in western states of Peninsular Malaysia.

Approval and waiver of informed consent was obtained from the Ethics Committee as no intervention was planned and confidentiality of patient information was maintained (NMRR-16-2033-32927). This study was supported by a research grant from the Ministry of Health Malaysia.

Patients were identified in March 2017. Daily laboratory data of serum creatinine of patients admitted from 12:01 am 1st March 2017 until 12:00 midnight 31st March 2017 was obtained from the pathology department of each hospital. A screening list was generated using STATA programme version 10 to identify potential patients fulfilling the criteria for AKI.²³ All the new admissions during this study period were screened for AKI using the Kidney Disease Improving Global Outcomes (KDIGO) 2012 definition of AKI.⁵ Urine output was excluded as a criterion for recruitment because it was not possible to obtain accurate records of urine output for patients in the general wards. Patients with AKI who were readmitted during the study period were excluded.

Nephrologists were not involved in the management of the patients unless a referral was made. Patients alerted by the screening process were reviewed within 48 hours. Clinical and

laboratory data from the patients' medical notes were reviewed and possible causes of AKI were identified.

Inclusion criteria for the study included hospitalised adults (18 years and older) who fulfilled the criteria for AKI during the study period. Patients with ESKD on dialysis and renal transplant patients or patients with increasing creatinine due to advancing CKD (as determined by the investigators) were excluded.

AKI was defined as an increase in serum creatinine of 0.3 mg/dl (26.5µmol/l) within 48 hours or an increase in serum creatinine to ≥ 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days.⁵

Baseline creatinine was defined as creatinine level at or within 7 days before the hospital admission, or the lowest creatinine (excluding the post dialysis creatinine if dialysis was initiated) during the index hospitalisation for those whose baseline creatinine were unknown.²⁴⁻²⁶

Serum creatinine concentration was measured by Jaffe method at six sites and kinetic enzymatic method at one site. The creatinine assay calibration was traceable to isotope dilution mass spectroscopy method.

Renal recovery was determined at hospital discharge. Full renal recovery was defined as return of serum creatinine to or below baseline or within 20% of baseline creatinine. Partial renal recovery was defined as serum creatinine which remained 20% above the baseline, but below 50% and not dialysis dependent or if previously required dialysis and is now dialysis independent. Failure to recover renal function was defined as serum creatinine remaining 50% above the baseline or dialysis dependence.²⁷ The total number of hospital admissions of adults (18 years and older) was compiled from the admissions office of each hospital.

The electronic records of the National Registration Department (NRD) were searched for deaths up till 31st December 2018. A search of the National Renal Registry (NRR) was also made to identify those who started on chronic dialysis up till 31st December 2018. Both NRD and NRR datasets included only Malaysian citizens.

Statistical analyses were performed using STATA version 10. Normally distributed continuous variables were described using mean and standard deviation, or median with interquartile range (IQR) for variables that were not normally distributed. Categorical data were described using proportions and percentages. Normally distributed data were analysed with t-test and one-way ANOVA. Categorical data were compared using a Pearson Chi-squared test. Data that were not normally distributed were analysed using Mann-Whitney U-test, Wilcoxon signed rank test, and Kruskal-Wallis test.

Univariate and multivariate survival analysis were performed using the likelihood ratio test of the stratified Cox proportional hazard model to determine the significance of covariates for the Malaysian cohort. Covariates included in the univariate analysis were age, gender, race, comorbid conditions (hypertension, diabetes mellitus, chronic lung disease, endocrine disease, malignancy, chronic liver disease, arthropathy, gastrointestinal disease, psychiatric disease, haematological disease, connective tissue disease, HIV infection), CKD, cardiovascular disease, neurological disease, primary aetiology (sepsis, prerenal, cardiorenal syndrome, obstructive uropathy, drug induced, hypertensive emergency, ischaemic acute tubular necrosis, hepatorenal syndrome, intratubular obstruction, glomerulonephritis, dengue, malaria, leptospirosis, contrast induced), history of exposure to nephrotoxic drugs, referral to nephrology, admission to ICU and dialysis dependence. Factors which were found to be significant were included in the multivariate analysis. Pvalue of <0.05 was considered statistically significant.

RESULTS

A total of 34,204 adult admissions were screened from seven hospitals, of which 2,457 developed AKI (incidence rate 7.18%) (Figure 1).

There were 1,480 (60.2%) males and the mean age on admission was 57.8 (\pm 17.5) years. The ethnic distribution reflects the general population but there were 109 foreigners (4.4%). The most common comorbidities were hypertension (55.0%), diabetes mellitus (46.6%), ischaemic heart disease (15.1%), chronic lung disease (12.2%) and CKD (12.0%) (Table I).

A sole aetiology was found in 1 902 (77.4%) while 22.5% had multiple causes for AKI. The common causes of AKI were sepsis (41.7%), prerenal (24.2%) and cardiorenal syndrome (10.8%).

The common causes of sepsis included pneumonia, diabetic foot ulcers, cellulitis, intra-abdominal sepsis and pyelonephritis/urinary tract infection. Prerenal causes included haemorrhage, acute gastroenteritis and dehydration. Cardiorenal syndrome was caused by cardiogenic shock, congestive heart failure, valvular heart disease and other cardiac diseases.

There were 175 cases of dengue fever, 20 with leptospirosis, one snake bite and malaria each, 72 with gastroenteritis and 17 pregnancy-related. Dengue contributed to 7.1% of AKI. The causes of pregnancy related AKI included preeclampsia, abruptio placenta, septic abortion, ruptured ectopic pregnancy and hyperemesis gravidarum.

At the diagnosis, 79.1% were at KDIGO stage 1, 9.7% were at stage 2 and 11.2% were at stage 3.

Exposure to nephrotoxins was reported in 760 (31%) of 2,457 patients and this included angiotensin converting enzyme inhibitors and angiotensin receptor blockers (432), diuretics (323), non-steroidal anti-inflammatory drugs (78), traditional medications (58), contrast media (51), aminoglycosides (9), other antibiotics (9), illicit drugs (10), antivirals (8) and antifungals (2). However, only 46 (1.9%) cases were deemed drug-associated AKI and 16 (0.7%) were related to contrast media.

The nephrology departments received 405 (16.5%) referrals for further clinical management. Of these referrals, 176 (43.4%) patients were started on RRT (Table II). A total of 404 (16.4%) AKI patients were admitted to ICU during their hospitalisation. Of these, 322 (13.1%) developed AKI while in ICU.

Patients needing dialysis made up 7.2% of the total AKI population and the majority (55.6%) were performed in the ICU. Acidosis (46.2%), uraemia (31.6%) and electrolyte disturbance (11.1%) were the commonest indications for RRT (Table III).

At the start of dialysis, the mean blood urea was 28.1 (\pm 12.1)mmol/l, serum creatinine was 548.5 (\pm 368.3) µmol/l and potassium were 4.63 (\pm 1.0)mmol/l. Of the 171 with full data 24 (14.0%) required continuous renal replacement therapy (CRRT) and 147 (86.0%) haemodialysis (HD) or slow low efficiency dialysis (SLED). A total of 20 patients on CRRT were on inotropic support and another two had intracranial bleed. Of the 24 patients on CRRT, 20 were on continuous veno-venous hemofiltration (CVVH) and two each were on continuous veno-venous haemodialysis (CVVHD) and hemodiafiltration (CVVHDF). The patients on CRRT made up 25.3% of those dialysed in ICU.

In-hospital mortality was 16.4% (404 deaths). At discharge, 74.7% of survivors had full renal recovery, 16.4% partial and 8.9% failed to recover. The mean serum creatinine on discharge was 119.5 (\pm 89.8) µmol/l. The average length of stay was 9.49 (\pm 11.4) days. Five patients still required haemodialysis on discharge (0.2% of all patients).

The outcome of 1,964 Malaysians from this cohort was traced from the NRD and NRR as of 31st December 2018 (89 foreigners were excluded and considered lost to follow-up at discharge). Mean follow-up of the total cohort was 13.74 (\pm 9.8) months, ranging from one day to 22 months and the median follow-up was 21.5 months. A total of 593 patients died after discharge from hospital (30.2%). Mortality was highest in the first 3 months of admission. Survival of the cohort at three months and one year was 71% and 63% respectively. A total of 38 patients (1.9% of those on followup) subsequently initiated chronic dialysis (34 HD, 4 peritoneal dialysis) (Table IV, Figure 2).

In the multivariate analysis, advanced age and having certain comorbidities increased the mortality risk. Mortality was higher in those with chronic liver disease (Hazard Ratio, HR 2.13, 95% Confidence Interval, 95%CI 1.63, 2.76), malignancy (HR 2.14, 95%CI 1.79, 2.55), neurological disease (HR 1.56, 95%CI 1.33, 1.84) and cardiovascular disease (HR 1.17, 95%CI 1.02, 1.35). In contrast, diabetes mellitus and CKD had no significant effect on mortality.

The risk was higher among foreigners (HR 3.02, 95%CI 1.91, 4.79). Hepatorenal syndrome (HR 1.94, 95%CI 1.24, 3.04), cardiorenal syndrome (HR 1.35, 95%CI 1.11, 1.65) and sepsis-associated AKI (HR 1.25, 95%CI 1.10, 1.43) were poor predictors for survival. Dengue fever (HR 0.13, 95%CI 0.05, 0.32) and ischaemic acute tubular necrosis (HR 0.35, 95%CI 0.17, 0.70) were associated with better outcomes.

Age (Man-SD) Gender 57.8 (±17.5) Male Female 1460 (60.2) Female 977 (9.8) Race 128 (52.2) Ordina 29 (2.2) Foreigner 109 (4.4) Others 16 (0.7) Comorbidity 2002 (81.5) Yes 2002 (81.5) No 458 (16.2) Diabetes mellitus 1144 (46.6) Chronic lung disease 299 (12.2) Endocrine disease 290 (12.2) Endocrine disease 20 (1.7) Age (10.0) (1.3) Malagnency 180 (0.7) Connective disease 20 (0.9) HV i	Parameters	No. (%)
Gindar id Male 1480 (60.2) Famile 977 (38.8) Rate 1783 (52.2) May 579 (23.6) Indian 459 (13.1) Foreigner 109 (4.4) Others 16 (0.7) Concrbidity 90 (3.5) General comorbidities 132 (55.0) Diabetes mellitus 134 (46.6) Chronic lung disease 234 (62.9) Chronic lung disease 234 (62.9) Chronic lung disease 324 (12.0) Chronic lung disease 32 (12.1) Phypertension 19 (2.4) Gastrointestinal disease 32 (12.0) Hypertension 19 (2.4) Gastrointestinal disease 32 (12.0) Hypertension 19 (2.4) Gastrointestinal disease 32 (12.0) Hypertension 10 (2.0) Hypertensitens disease	Age (Mean±SD)	57.8 (±17.5)
Male 1480 (60.2) Female 977 (13.8) Ree 978 (23.6) Online 459 (13.1) Foreigner 109 (14.1) Others 160 (0.7) Others 160 (0.7) Ves 2002 (81.5) No 355 (15.5) Proteigner 1320 (53.0) Others 1323 (53.0) Diabetes mellitus 1144 (46.6) Chronic lung disease 299 (12.2) Endocrine disease 299 (12.3) Malignancy 194 (7.3) Others 12.1 Psychiatric disease 21 (2.1) Hermatological disease 24 (1.0) Connective time disease 24 (1.0) Protein (Liftery disease 24 (1.0)	Gender	
Feerale 97 (38.) Malay 1283 (52.2) Malay 1283 (52.2) Chinese 97 (32.6) Foreingner 400 (4.1) Others 100 (6.7) Comorbidity 7 Yes 2020 (81.5) No 455 (15.5) No 455 (15.5) Chronic long disease 239 (12.2) Endocrine disease 344 (46.6) Chronic long disease 344 (46.6) Chronic long disease 344 (46.6) Chronic long disease 344 (19.9) Chronic long disease 35 (2.1) Gastromtestrial mease 35 (2.1) Gastromtestrial mease 35 (2.0) Hyli Infection 18 (0.7) Connective tissue disease 74 (3.0) Protrate disease 74 (3.0) Protrate disease 74 (3.0) Obstructive uropathy 6 (0.2) Protrate disease 74 (3.0) Obstructive uropathy 6 (0.2) Protrate disease 74 (3.0) Obstruct	Male	1480 (60.2)
Rece J Malay 1523 (52.2) Chinese 579 (23.6) Indust 159 (23.6) Indust 160 (0.7) Otherse 160 (0.7) Otherse 2002 (81.5) No 425 (15.5) General comorbidites 1144 (65.6) Hypertensite 244 (8.9) Malay 1144 (65.6) Dabatets mellitus 1144 (67.9) Chronic Illerd Giesse 29 (2.4) Gastrointestinal disease 22 (1.3) Arthropathy 59 (2.4) Gastrointestinal disease 24 (1.0) Harmantological disease 24 (1.0) Harmantological disease 24 (1.0) Horinic Kindrey disease 24 (1.0) Chronic Kindrey disease 24 (1.0) Chronic Kindrey disease 24 (1.0) Chronic Kindrey disease 24 (1	Female	977 (39.8)
Malay 1283 (52.2) Chinese 409 (23.6) Chinese 409 (23.6) Foreigner 60 (4.1) Others 10 (6.7) Comorbidity 7 Yes 2002 (81.5) No 455 (18.5) Chronic long disease 299 (12.2) Endocrine disease 244 (46.6) Chronic long disease 244 (3.9) Malignancy 194 (4.6.0) Chronic long disease 244 (1.0) Chronic long disease 22 (0.3) Arthropath 181 (4.6.0) Chronic long disease 22 (0.9) HV infection 181 (0.7) Concettve tissue disease 24 (1.0) Concettve tissue disease 24 (1.0) Concettve tissue disease 24 (1.0.0) Provise discue disease 74 (3.0.0) Unrishinat 10.0.0 Neurogenic bladder 10.0.0 Obstructive uropathy 6 (0.2.1) Prestate disease 2 (0.1) Edment Chanal disease 2 (0.1)	Race	
Currente 3.9 (2.8.9) Indian 4.0 (2.4.9) Indian 10 (0.7) Others 10 (0.7) No 2002 (01.5.) No 455 (2.8.9) Pypertension 1144 (46.9.1) Diabetes mellitus 1144 (46.9.1) Endocrine disease 224 (4.9.1) Chronic lurer disease 234 (4.9.1) Chronic lurer disease 234 (4.9.1) Gastrointestinal disease 23 (1.3.1) Gastrointestinal disease 23 (1.3.1) Read Comobidities 23 (1.3.1) Chronic kidney disease 24 (1.0.1) Prostate disease 23 (1.3.1) Chronic kidney disease 24 (1.2.0) Prestate disease 23 (1.3.1) Chronic kidney disease 23 (1.3.1) Preto	Malay	1283 (52.2)
Interview 100 (12.7) Control file 16 (0.7) Comorbidity 16 (0.7) Yes 2002 (81.5) No 455 (18.5) Hypertension 1352 (25.0) Diabetes mellitus 1144 (46.6) Chronic lung disease 239 (12.2) Endocrine disease 239 (12.2) Arthropathy 90 (5.7) Gastrointestinal disease 23 (1.3) Hermatological disease 22 (0.9) HV/infection 18 (0.7) Psychiatric disease 22 (2.0) HV infection 18 (0.7) Real conscriptions 24 (1.0) Urolipical malignancy 8 (0.3) Obstructive uropathy 6 (0.2) Pyeloatric disease 22 (0.9) Urolipical malignancy 8 (0.3) Obstructive uropathy 6 (0.2) Paelonomotidities 10.00 Urolipical malignancy 20 (2.5) Congenital heart disease 20 (0.8) Valuar heart disease 13 (0.5) Cardio ascular comorbidities	Chinese	5/9 (23.6)
Others 16 (0.7) Yes 2002 (81.5) No 455 (18.5) General conorbidites 1132 (55.0) Diabetes mellitus 1144 (46.6) Chronic lung disease 296 (12.2) Endocrine disease 244 (9.9) Chronic lung disease 291 (12.2) Endocrine disease 291 (12.2) Chronic lung disease 291 (12.2) Chronic lung disease 291 (12.2) Gastroinstriking disease 29 (12.0) Psychiatric disease 29 (12.0) Protective fisue disease 22 (0.9) HV infection 18 (0.7) Renal Comorbidities 294 (12.0) Orner kidney disease 294 (12.0) Protective fisue disease 24 (2.0) Uroiltitiais 48 (2.0) Uroiltitiais 10 0.0 Neurogenic bladder 10 (0.0) Neurogenic bladder 2 (0.1) Cardiovascular comorbidities 21 (0.1) Congenical heart disease 22 (0.9) Protheard vacular disease 23 (3.1)	Foreigner	109 (19.1)
Comorbidity Yes 2002 (81.5) No 455 (18.5) Hypertension Diabetes mellitus Chronic lung disease 295 (12.2) Diabetes mellitus Chronic lung disease 295 (12.2) Malignery 194 (46.6) Chronic lung disease 295 (12.2) Malignery 194 (2.3) Chronic liver disease 295 (2.4) Gastrointestinal disease 395 (2.4) Gastrointestinal disease 312 (1.3) Heamatological disease 22 (0.9) HV infection 184 (2.0) HV i	Others	16 (0.7)
Yes 2002 (81.5) General comorbidities 9 Hypertension 1352 (55.0) Diabetes mellitus 1144 (46.6) Chronic lung disease 290 (12.2) Endocrine disease 244 (3.9) Obstatus 39 (2.4) Gastroniteristinal disease 21 (1.3) Arthropathy 39 (2.4) Gastroniteristinal disease 22 (0.9) How in the disease 22 (0.9) HV infection 18 (0.7) Renal comorbidities 20 (12.0) Chronic kidney disease 24 (1.0) Connective tissue disease 22 (0.9) HV infection 18 (0.7) Renal comorbidities 20 (12.0) Protoxic disease 24 (1.0) Obstructive urganthy 6 (0.2) Congenital heart disease 271 (15.1) Congenital heart disease 270 (0.3)	Comorbidity	
No 455 (18.5) Hypertension 1352 (55.0) Diabetes mellitus 1144 (46.6) Chronic lung disease 299 (12.2) Endocrine disease 299 (12.3) Maligrancy 194 (7.3) Chronic lung disease 90 (3.4) Garcine luver disease 90 (3.4) Garcine luver disease 21 (3.1) Garcine luver disease 22 (0.9) HV infection 18 (0.7) Real comobidities 20 (12.2) Connic kidney disease 22 (0.9) HV infection 18 (0.7) Real comobidities 20 (12.0) Urological malignancy 8 (0.3) Urological malignancy 8 (0.2) Urological malignancy 8 (0.3) Urological malignancy 8 (0.3) Urological malignancy 8 (0.3)	Yes	2002 (81.5)
General comorbidities 1352 (55.0) Hypertension 1352 (55.0) Diabetes mellitus 1144 (46.6) Chronic lung disease 299 (12.2) Endocrine disease 294 (3.9) Malignarcy 194 (7.9) Chronic lung disease 90 (3.7) Arthropath 59 (2.4) Gastrointestinal disease 92 (1.0) Prostate disease 22 (0.9) HW infection 184 (2.0) Chronic kinking disease 29 (12.0) Prostate disease 24 (1.0) Prostate disease 24 (1.0) Prostate disease 74 (3.0) Urolichiais 48 (2.0) Urolichiais 10.0.0 Obstructive uropathy 6 (0.2) Pyelonephritis 1 (0.0) Neurogenic bladder 10.0.0 Others 2 (0.1) Cardiovascular comorbidities 21 (0.1) Ischemic heart disease 21 (0.2) Prepheral vascular disease 20 (0.3) Valvalor heart disease 20 (0.3) Valvalor hea	No	455 (18.5)
hypertension 1322 (55.0) Diabetes mellitus 1144 (46.6) Chronic lung disease 299 (12.2) Endocrine disease 244 (33) Mingmary 194 (23) Mingmary 194 (23) Mingmary 194 (23) Arthropathy 59 (2.4) Gastrointestinal disease 22 (1.3) Heamatological disease 22 (0.9) HV infection 18 (0.7) Real comobilities 20 (2.0) Real comobilities 22 (0.9) HV infection 18 (0.7) Real comobilities 48 (2.0) Urological malignancy 6 (0.2) Obstructive uropathy 6 (0.2) Perionaphritis 1 (0.0) Neurogenic bladder 2 (0.1) Condicities 2 (0.9) Perionaphritis 1 (0.0) Research 2 (0.9) Perionaphritis 1 (0.0) Research 2 (0.9) Peripheral vascular disease 2 (0.9) Condiciti science 2 (0.9)	General comorbidities	
Datacets intentus1144 (48.0)Chronic lung disease294 (12.2)Endocrine disease244 (5.9)Chronic lung disease90 (3.7)Arthropathy90 (3.7)Arthropathy90 (3.7)Arthropathy91 (2.1)Psychiatric disease22 (1.3)Haematological disease22 (0.9)HW infection18 (0.7)Renat comorbidities24 (1.0)Chronic kinker disease22 (0.9)HW infection18 (0.7)Renat comorbidities48 (2.0)Urolichiasis48 (2.0)Urolichiasis48 (2.0)Urolichiasis48 (2.0)Urolichiasis10.00Obstructive uropathy6 (0.2)Pyelonephritis10.00Obstructive uropathy62 (2.5)Congenical comorbidities21 (1.1)Ischemic heart disease22 (0.9)Keurogenic bladder10.00Chronic king disease22 (0.9)KotkerTranisent schemic attack197 (8.0)Congenical comorbidities20 (0.1)Others7 (0.3)StrokerTranisent schemic attack197 (8.0)Chronic kingte emergency45 (1.9)Miscellaneous comorbidities41 (1.7)Primary aetiology of XI19 (0.8)Dengue175 (7.1)Others19 (0.8)Dengue175 (7.1)Others20 (0.8)Dengue175 (7.1)Others19 (0.8)Dengue175 (7.1)Distructive uropathy19 (0.8) </td <td>Hypertension Disketes molliture</td> <td>1352 (55.0)</td>	Hypertension Disketes molliture	1352 (55.0)
Choice fund guidesage 299 (12.4) Endocrine disease 299 (12.4) Medigram, 194 (7.9) Artmonic live disease 99 (2.4) Artmonic live disease 99 (2.4) Artmonic live disease 99 (2.4) Artmonic disease 99 (2.4) Artmonic disease 99 (2.4) Connective disease 24 (1.0) Connective disease 24 (1.0) Connective disease 24 (1.0) Prostate disease 24 (1.0) Obstructive uropathy 6 (0.2) Prostate disease 71 (15.1) Congestive heart failure 13 (5.5) Cardioxascular comorbidities 21 (0.1) Schwein heart disease 22 (0.9) Valuar heart disease 22 (0.9) Valuar heart disease 21 (15.1) Congestive heart failure 133 (5.4) Cardioxascular comorbidities 21 (0.1) Chronic kinder disease 20 (0.8) Valuar heart disease 23 (0.3) Valuar heart disease 13 (0.5) Congestive heart failure	Diabetes mellitus Chronic lung disease	1144 (46.6)
Mainpaner194 (7.8)Chronic liver disease90 (3.7)Arthropathy95 (2.4)Gastrichtershal disease32 (1.3)Pophiatric disease22 (0.9)Hiematological disease22 (0.9)HW infection18 (0.7)Renal comorbidities24 (1.20)Prostate disease24 (1.20)Prostate disease24 (1.20)Urolithisais48 (0.3)Urolithisais10.00Urolithisais10.00Obstructive uropathy6 (0.2)Pydonephritis10.00Neurogenic bladder10.00Others20 (1.1)Cardiovascular comorbidities371 (15.1)Ishemic heart disease22 (0.9)Prepriperal vascular disease22 (0.9)Peripheral vascular disease20 (0.8)Valvular heart disease30 (0.1)Miscellaneous comorbidities11 (1.7)Premal70 (3.1)StrokeTraisent ischaremic attack197 (8.0)Chronic neurological diseases36 (1.9)Preprinti10 (2.2) (1.7)Preprenal25 (2.1)Cardiorenal syndrome26 (1.08)Dengue75 (7.1)Obstructive uropathy96 (3.9)Progenal induce dist19 (0.8)Contrast induced Akl16 (0.7)Hepat	Endocrine disease	233 (12.2)
Chrönic liver disease 90 (3.7) Arthropathy 99 (2.4) Gastrointestinal disease 32 (1.3) Haematological disease 22 (0.9) HV infection 18 (0.7) Renat ComoDidities 22 (0.9) HV infection 18 (0.7) Renat ComoDidities 24 (1.0) Chronic Kidney disease 24 (1.20) Prostate disease 24 (1.20) Urological malignancy 8 (0.3) Obstructive uropathy 6 (0.2) Pysionephritis 1 (0.0) Neurogenic bladder 1 (0.0) Outrodiscut comorbidities 2 (0.1) Cardioxascular comorbidities 3 (1.15.1) Congestive heart failure 133 (5.4) Cardioxascular comorbidities 2 (0.0) Valvular heart disease 2 (0.0) Valvular heart disease 3 (0.1) Others 2 (0.1) StrokeTransient ischaemic attack 197 (8.0) Chronic neurysm 2 (0.1) Others 3 (0.1) Miscolanocus comorbidities 10 (1.7)	Malignancy	194 (7.9)
Arthropathy 59 (2.4) Gastrointestinal disease 52 (1.3) Psychiatric disease 32 (1.3) Heamatological disease 22 (0.9) HIV infection 18 (0.7) Renal comorbidities 74 (3.0) Chronic kindrey disease 74 (3.0) Urolithiasis 10.0.0 Neurogenic bladder 10.0.0 Obstructive uropathy 6 (0.2) Pycionephritis 10.0.0 Neurogenic bladder 10.0.0 Others 20 (0.1) Cardiovascular comorbidities 20 (0.1) Khemic heart disease 23 (0.5) Adric aneurysm 22 (2.9) Peripheral vascular disease 23 (0.1) Valvalar heart disease 23 (0.1) Others 70 (0.3) Stroke/Transenti schaemic attack 197 (8.0) Chronic neurological diseases 3 (0.1) Miscellaneou	Chronic liver disease	90 (3.7)
Gastrointestinal disease 35 (2.1) Haematological disease 22 (0.9) HV infection 18 (0.7) Renal comorbidities 29 (12.0) Prostate disease 74 (3.0) Urological disease 74 (3.0) Urological malignancy 8 (0.3) Obstructive uropathy 6 (0.2) Pyelonephritis 1 (0.0) Neurogenic bladder 1 (0.0) Other at disease 2 (0.1) Cardioxascular comorbidities 2 (0.1) Cardioxascular disease 2 (0.1) Cardioxascular disease 2 (0.2) Valvular heart disease 2 (0.1) Cardioxascular disease 2 (0.1) Cardioxascular disease 2 (0.1) Cardioxascular disease 2 (0.1) Cardioxascular disease 2 (0.2) Cortic aneurysm 2 (0.1) Others	Arthropathy	59 (2.4)
Psychiatric disease 22 (1.3) Haematological disease 22 (0.9) Connective tissue disease 22 (0.9) Prostate disease 29 (12.0) Prostate disease 74 (3.0) Urrolithiasis 74 (3.0) Obstructive uropathy 6 (0.2) Pyelonephritis 1 (0.0) Neurogenic bladder 1 (0.0) Others 20 (0.1) Cardiovascular comorbidities 21 (0.1) Congenita heart disease 22 (0.9) Peripheral vascular disease 23 (0.1) Valual heart disease 23 (0.1) Others 7 (0.3) Neurological diseases 24 (0.1) Others 7 (0.3) Peripheral vascular disease 23	Gastrointestinal disease	51 (2.1)
Haematological disease 24 (1.0) Connective tissue disease 22 (0.9) HV infection 18 (0.7) Renal comorbidities 2 Chronic kidney disease 294 (12.0) Prostate disease 74 (3.0) Urological malignancy 68 (0.3) Obstructive uropathy 6 (0.2) Pyelonephritis 1 (0.0) Neurogenic bladder 1 (0.0) Cardioxescular comorbidities 2 (0.1) Escheric heart disease 22 (0.9) Congenital heart disease 20 (0.8) Valuar heart disease 3 (0.1) Others 3 (0.1) Others 3 (0.1) <t< td=""><td>Psychiatric disease</td><td>32 (1.3)</td></t<>	Psychiatric disease	32 (1.3)
Connective tissue disease 22 (0.9) HW infection 18 (0.7) Renal comorbidities 74 (3.0) Chronic kidney disease 74 (3.0) Prostate disease 74 (3.0) Urolithiasis 48 (2.0) Urolithiasis 48 (2.0) Urolithiasis 10.0.0 Obstructive uropathy 6 (0.2) Pyelonephritis 1 (0.0) Neurogenic bladder 1 (0.0) Others 2 (0.1) Cardiovascular comorbidities 31 (5.4) Congenitic heart disease 22 (0.9) Peripheral vascular disease 22 (0.9) Peripheral vascular disease 22 (0.9) Valvular heart disease 2 (0.1) Others 7 (8.0) Chronic neuropism 2 (0.1) Others 3 (0.1) Muscella comorbidities 41 (1.7) Priveral schaemic attack 197 (8.0) Chronic neuropisci diseases 54 (2.2) Others 3 (0.1) Miscellaneous comorbidities 41 (1.7) Privera	Haematological disease	24 (1.0)
Real comol/dities 10 (U/) Renal comol/dities 294 (12.0) Prostate disease 294 (12.0) Prostate disease 294 (12.0) Urological malignancy 88 (0.3) Obstructive uropathy 6 (0.2) Pyelonephritis 1 (0.0) Neurogenic bladder 1 (0.0) Cardiovascular comobidities 2 (0.1) Cardiovascular comobidities 2 (0.1) Cardiovascular comobidities 2 (0.2) Ischemic heart disease 2 (0.3) Congestive heart failure 13 (5.4) Cardiac arhythmias 62 (2.5) Congenital heart disease 2 (0.0) Valvular heart disease 2 (0.0) Valvular heart disease 2 (0.1) Chronic neurological diseases 2 (2.2) Others 7 (0.3) Neurological comobidities 7 (0.3) Stroke/Traisent ischaemic attack 197 (8.0) Chronic neurological diseases 5 4 (2.2) Others 3 (0.1) Sepsia associated Akl 10.3 Prerenal	Connective tissue disease	22 (0.9)
Chronic kidney disease 294 (12.0) Prostate disease 74 (3.0) Urolithiasis 48 (2.0) Urolithiasis 8 (0.3) Obstructive uropathy 6 (0.2) Pyelonephritis 1 (0.0) Neurogenic bladder 1 (0.0) Cardiovascular comorbidities 20 (0.1) Ischemic heart disease 371 (15.1) Congestive heart failure 133 (5.4) Cardiovascular disease 20 (0.8) Valuuar heart disease 20 (0.8) Valuuar heart disease 20 (0.8) Valuuar heart disease 20 (0.1) Valuuar heart disease 20 (0.1) Valuuar heart disease 20 (0.3) Actric aneurysm 2 (0.1) Actric aneurysm 2 (0.1) Stroke/Transient ischaemic attack 19 7 (8.0) Chronic neurological diseases 3 (0.1) Miscellaneous comorbidities 3 (0.1) Perienal 255 (2.2) Others 3 (0.1) Dengue 175 (7.1) Dengue 255 (1.2)	Renal comorbidities	18 (0.7)
Prostate diseaseTUroligical malignancy8 (0.3)Obstructive uropathy6 (0.2)Pyelonephritis1 (0.0)Neurogenic bladder1 (0.0)Cardiovascular comorbidities1Ischemic heart disease2 (0.1)Cardiovascular comorbidities13 (5.4)Cardiovascular comorbidities13 (5.4)Cardiovascular disease22 (0.9)Penipheral vascular disease20 (0.8)Valvular heart disease20 (0.8)Valvular heart disease2 (0.1)Others2 (0.1)Others2 (0.1)Others2 (0.1)Others3 (0.5)Aortic aneurysm2 (0.1)Others3 (0.5)Adric aneurysm2 (0.1)Others3 (0.1)Miscellaneous comorbidities41 (1.7)Primary aetiology of AKI1023 (41.7)Premania595 (24.2)Cardiorenal syndrome266 (10.8)Dengue175 (7.1)Obstructive uropathy95 (3.9)Drug associated AKI1023 (41.7)Premal256 (10.8)Dengue13 (1.3)Leptospirosis42 (1.7)Hypertenal syndrome260 (10.8)Dengue13 (1.3)Leptospirosis42 (1.7)Hypertenal syndrome19 (0.8)Gomerulonephritis19 (0.8)Gomerulonephritis19 (0.8)Gomerulonephritis19 (0.8)Gomerulonephritis19 (0.8)Gomerulonephritis19 (0.8) <td< td=""><td>Chronic kidney disease</td><td>294 (12.0)</td></td<>	Chronic kidney disease	294 (12.0)
Urolithiasis 48 (2.0) Urological malignancy 8 (0.3) Obstructive uropathy 6 (0.2) Pyelonephritis 1 (0.0) Neurogenic bladder 1 (0.0) Others 2 (0.1) Cardiovascular comorbidities 313 (5.4) Congenital heart disease 22 (0.9) Peripheral vascular disease 20 (0.8) Valvular heart disease 20 (0.8) Valvular heart disease 20 (0.1) Others 2 (0.1) Stroke/Transient ischaemic attack 197 (8.0) Others 3 (0.1) Miscellaneous comorbidities 3 (0.1) Miscellaneous comorbidities 3 (0.1) Primary aetiology of AKI 3 (0.1) Primary aetiology of AKI 1023 (41.7) Prenal 595 (24.2) Cardiorenal syndrome 265 (10.8) Dengue 105 (54.2) Others 3 (0.1) Miscellaneous comorbidities 3 (0.1) Intrastruction 1095 (24.2) Cardiorenal syndrome 265 (10.8) <	Prostate disease	74 (3.0)
Urological malignancy 8 (0.3) Obstructive uropathy 6 (0.2) Pyelonephritis 1 (0.0) Neurogenic bladder 2 (0.1) Cardiovascular comorbidites 2 (0.1) Ischemic heart disease 371 (15.1) Congestive heart failure 133 (5.4) Cardiac arrhythmias 62 (2.5) Congenital heart disease 22 (0.9) Peripheral vascular disease 20 (0.8) Valvular heart disease 2 (0.1) Others 7 (0.3) Primary actiology of AKI 197 (8.0) Primary actiology of AKI 197 (8.0) Primary actiology of AKI 1023 (41.7) Prepais associated AKI 1023 (41.7) Prerenal 266 (10.8) Dengue 175 (7.1) Obstructive uropathy 263 (3) Drug associated AKI 46 (1.9) Hypertenal syndrome	Urolithiasis	48 (2.0)
Obstructive uropathy 6 (0.2) Pyelonephritis 1 (0.0) Neurogenic bladder 2 (0.1) Cardiovascular comorbidities 2 (0.1) Ischemic heart disease 371 (15.1) Congenic bladder 13 (5.4) Cardiac arrhythmias 62 (2.5) Congenital heart disease 20 (0.8) Valvular heart disease 20 (0.8) Valvular heart disease 20 (0.3) Verological comorbidities 7 (0.3) Burological comorbidities 3 (0.1) Miscellaneous comorbidities 3 (0.1) Miscellaneous comorbidities 3 (1.7) Primary aetiology of AKI 1023 (41.7) Sepsis associated AKI 1023 (41.7) Prenenal 595 (24.2) Cardiorenal syndrome 266 (10.8) Dengue 175 (7.1) Obstruct	Urological malignancy	8 (0.3)
Pyelonephritis 1 (0.0) Neurogenic bladder 1 (0.0) Others 2 (0.1) Exchemic heart disease 2 (0.1) Cardiovascular comorbidities 33 (5.4) Cardiac arrhythmias 62 (2.5) Congenital heart disease 20 (0.8) Valvular heart disease 20 (0.8) Valvular heart disease 2 (0.1) Others 7 (0.3) Neurogotid comorbidities 7 (0.3) Stroke/Transient ischaemic attack 197 (8.0) Chronic neurological diseases 54 (2.2) Others 3 (0.1) Miscellaneous comorbidities 41 (1.7) Primary aetiology of AKI 1023 (41.7) Prerenal 595 (24.2) Cardiorenal syndrome 266 (10.8) Dengue 175 (7.1) Obstructive uropathy 96 (3.9) Drug associated AkI 46 (1.9) Hypertensive emergency 45 (1.8) Ischemic acute tubular necrosis 42 (1.7) Hepatorenal syndrome 20 (0.8) Intratubular obstruction <t< td=""><td>Obstructive uropathy</td><td>6 (0.2)</td></t<>	Obstructive uropathy	6 (0.2)
Neurogenic bladder Others1 (0.0)Cardiovascular comorbidities2 (0.1)Ischemic heart disease371 (15.1)Congestive heart failure133 (5.4)Cardiac arrhythmias62 (2.5)Congenital heart disease20 (0.8)Valvular heart disease20 (0.8)Valvular heart disease20 (0.8)Valvular heart disease13 (0.5)Aortic aneurysm2 (0.1)Others7 (0.3)Neurological comorbidities54 (2.2)Stroke/Transient ischaemic attack197 (8.0)Chronic neurological diseases54 (2.2)Others3 (0.1)Miscellaneous comorbidities41 (1.7)Primary aetiology of AKI1023 (41.7)Premenal595 (24.2)Cardiorenal syndrome266 (10.8)Dengue175 (7.1)Obstructive uropathy96 (3.9)Drug associated AKI46 (1.9)Hypertensive emergency45 (1.8)Ischemic acute tubular necrosis42 (1.7)Hepatorenal syndrome31 (1.3)Leptospirosis20 (0.8)Intratubular obstruction19 (0.8)Gomerulonephritis19 (0.8)Gomerulonephritis19 (0.8)Gomerulonephritis19 (0.8)Gomerulonephritis19 (0.4)Gomerulonephritis19 (0.4)Contrast induced AKI16 (0.7)Malaria1 (0.1)Others60 (2.4)KDIGO stage AT AKI diagnosis1237 (9.7)1237 (9.7)3726 (11.	Pyelonephritis Naura pagis bladdar	1 (0.0)
Contents2 (0,1)Cardiovascular comorbidities371 (15.1)Schemic heart disease371 (15.1)Congestive heart failure133 (5.4)Cardiac arrhythmias62 (2.5)Congenital heart disease20 (0.8)Valvular heart disease20 (0.8)Valvular heart disease20 (0.1)Others7 (0.3)Neurological comorbidities7 (0.3)Stroke/Transient ischaemic attack197 (8.0)Chronic neurological diseases54 (2.2)Others3 (0.1)Miscellaneous comorbidities11 (1.7)Primary aetiology of XKI1023 (41.7)Prerenal255 (24.2)Cardiorenal syndrome266 (10.8)Dengue175 (7.1)Obstructive uropathy96 (3.9)Drug associated AKI46 (1.9)Hypertensive emergency45 (1.8)Ischerenal syndrome31 (1.3)Leptospirosis42 (1.7)Hepatorenal syndrome31 (1.3)Leptospirosis42 (1.7)Hepatorenal syndrome19 (0.8)Intratubular obstruction19 (0.8)Gomerulonephritis19 (0.8)Gomerulonephritis19 (0.8)Gomerulonephritis19 (0.8)Gomerulonephritis19 (0.2)Malaria1 (0.1)Others60 (2.4)Malaria1 (0.1)Others60 (2.4)Mean baseline serum creatinine (umol/)1942 (479.8)	Neurogenic bladder	1 (0.0)
Bit NutriceThe second seco	Cardiovascular comorbidities	2 (0.1)
Congestive heart failure133 (5.4)Cardiac arrhythmias62 (2.5)Congenital heart disease22 (0.9)Peripheral vascular disease20 (0.8)Valvular heart disease20 (0.1)Valvular heart disease2 (0.1)Others7 (0.3)Burological comorbidities97 (8.0)Chronic neurological diseases54 (2.2)Others3 (0.1)Miscellaneous comorbidities41 (1.7)Primary actiology of KI1023 (41.7)Sepsis associated AKI1023 (41.7)Premal256 (10.8)Dengue175 (7.1)Obstructive uropathy96 (3.9)Drug associated AKI45 (1.8)Ischemic acute tubular necrosis42 (1.7)Hepatorenal syndrome31 (1.3)Leptospirosis10 (0.8)Intratubular obstruction19 (0.8)Gomerulonephritis19 (0.8)Gomerulonephritis10 (0.7)Malaria1 (0.1)Others60 (2.4)KDIGO stage AT AKI diagnosis1044 (79.1)123 (3.9, 0.7)3276 (11.2)Mean baseline serum creatinine (µmol/)1042 (27.0.8)	Ischemic heart disease	371 (15.1)
Gardiac arrhythmias62 (2.5)Congenital heart disease22 (0.9)Peripheral vascular disease20 (0.8)Valvular heart disease13 (0.5)Aortic aneurysm2 (0.1)Others7 (0.3)Stroke/Transient ischaemic attack197 (8.0)Chronic neurological diseases54 (2.2)Others3 (0.1)Miscellaneous comorbidities41 (1.7)Primary aetiology of AKI1023 (41.7)Sepsis associated AKI1023 (41.7)Prerenal295 (24.2)Cardiorenal syndrome266 (10.8)Dengue175 (7.1)Obstructive uropathy96 (3.9)Drug associated AKI46 (1.9)Hypertensive emergency45 (1.8)Ischaemic acute tubular necrosis42 (1.7)Hepatorenal syndrome31 (1.3)Leptospirosis20 (0.8)Intratubular obstruction19 (0.8)Golmerulonephritis91 (0.8)Golmerulonephritis19 (0.8)Golmeral syndrome1 (0.1)Others60 (2.4)KDIGO stage AT AKI diagnosis1944 (79.1)123 (9.7)2237 (9.7)3276 (11.2)	Congestive heart failure	133 (5.4)
Congenital heart disease22 (0.9)Peripheral vascular disease20 (0.8)Valvular heart disease13 (0.5)Aortic aneurysm2 (0.1)Others7 (0.3)Neurological comorbidities97 (8.0)Chronic neurological diseases54 (2.2)Others3 (0.1)Miscellaneous comorbidities41 (1.7)Primary aetiology of Akl1023 (41.7)Sepsis associated Akl1023 (41.7)Prerenal595 (24.2)Cardiorenal syndrome266 (10.8)Dengue175 (7.1)Obstructive uropathy96 (3.9)Durg associated Akl42 (1.7)Hypertensive emergency45 (1.8)Ischaemic acute tubular necrosis42 (1.7)Hepatorenal syndrome31 (1.3)Leptospirosis20 (0.8)Intratubular obstruction19 (0.8)Contrast induced Akl16 (0.7)Malaria1 (0.1)Others60 (2.4)KDIGO stage AT Akl diagnosis237 (9.7)A237 (9.7)A237 (9.7)A276 (11.2)	Cardiac arrhythmias	62 (2.5)
Peripheral vascular disease20 (0.8)Valvular heart disease13 (0.5)Aortic aneurysm2 (0.1)Others7 (0.3)Neurological comorbidities7Stroke/Transient ischaemic attack197 (8.0)Chronic neurological diseases3 (0.1)Miscellaneous comorbidities41 (1.7)Primary aetiology of AKI1023 (41.7)Prerenal595 (24.2)Cardiorenal syndrome266 (10.8)Dengue175 (7.1)Obstructive uropathy96 (3.9)Drug associated AKI46 (1.9)Hypertensive emergency45 (1.8)Ischaemic actue tubular necrosis42 (1.7)Hepatorenal syndrome31 (1.3)Leptospirosis20 (0.8)Intratubular obstruction19 (0.8)Gordioneral syndrome31 (1.3)Leptospirosis20 (0.4)Malaria1 (0.1)Others60 (2.4)KDIGO stage AT AKI diagnosis1944 (79.1)2237 (9.7)Mean baseline serum creatinine (µmol/l)1042.2 (2.70.8)	Congenital heart disease	22 (0.9)
Valvular heart disease13 (0.5)Aortic aneurysm2 (0.1)Others7 (0.3)Neurological comorbidities7Stroke/Transient ischaemic attack197 (8.0)Chronic neurological diseases54 (2.2)Others3 (0.1)Miscellaneous comorbidities41 (1.7)Primary aetiology of AKI1023 (41.7)Prenenal595 (24.2)Cardiorenal syndrome266 (10.8)Dengue175 (7.1)Obstructive uropathy96 (3.9)Drug associated AKI46 (1.9)Hypertensive emergency45 (1.8)Ischaemic acute tubular necrosis42 (1.7)Hepatorenal syndrome31 (1.3)Leptospirosis20 (0.8)Intratubular obstruction19 (0.8)Glomerulonephritis19 (0.8)Contrast induced AKI10(.1)Others60 (2.4)KDIGO stage AT AKI diagnosis1044 (79.1)123237 (9.7)2237 (9.7)4ean baseline serum creatinine (µmol/l)104.2 (±70.8)	Peripheral vascular disease	20 (0.8)
Actic alredings2 (0.1)Others7 (0.3)Neurological comorbidities7 (8.0)Stroke/Transient ischaemic attack197 (8.0)Chronic neurological diseases54 (2.2)Others3 (0.1)Miscellaneous comorbidities41 (1.7)Primary aetiology of AKI1023 (41.7)Sepsis associated AKI1023 (41.7)Prerenal595 (24.2)Cardiorenal syndrome266 (10.8)Dengue175 (7.1)Obstructive uropathy96 (3.9)Drug associated AKI46 (1.9)Hypertensive emergency45 (1.8)Ischaemic acute tubular necrosis42 (1.7)Hepatorenal syndrome31 (1.3)Leptospirosis20 (0.8)Intratubular obstruction19 (0.8)Gomerulonephritis19 (0.8)Contrast induced AKI16 (0.7)Malaria1 (0.1)Others60 (2.4)KDIGO stage AT AKI diagnosis1944 (79.1)123 (276 (11.2)Mean baseline serum creatinine (µmol/l)104.2 (±70.8)	Valvular heart disease	13 (0.5)
Neurological comorbiditiesStroke/Transient ischaemic attack197 (8.0)Chronic neurological diseases54 (2.2)Others3 (0.1)Miscellaneous comorbidities41 (1.7)Primary aetiology of AKI1023 (41.7)Sepsis associated AKI1023 (41.7)Prerenal595 (24.2)Cardiorenal syndrome266 (10.8)Dengue175 (7.1)Obstructive uropathy96 (3.9)Drug associated AKI45 (1.8)Ischaemic acute tubular necrosis42 (1.7)Hepatorenal syndrome20 (0.8)Intratubular obstruction19 (0.8)Golmerulonephritis19 (0.8)Contrast induced AKI16 (0.7)Malaria1 (0.1)Others60 (2.4)KDIGO stage AT AKI diagnosis1944 (79.1)1237 (9.7)3276 (11.2)Mean baseline serum creatinine (µmol/l)104.2 (±70.8)	Others	7 (0 3)
Stroke/Transient ischaemic attack197 (8.0)Chronic neurological diseases54 (2.2)Others3 (0.1)Miscellaneous comorbidities3 (0.1)Primary aetiology of AKI1023 (41.7)Prenenal595 (24.2)Cardiorenal syndrome266 (10.8)Dengue175 (7.1)Obstructive uropathy96 (3.9)Drug associated AKI46 (1.9)Hypertensive emergency45 (1.8)Ischaemic acute tubular necrosis42 (1.7)Hepatorenal syndrome31 (1.3)Leptospirosis20 (0.8)Intratubular obstruction19 (0.8)Gomerulonephritis19 (0.8)Contrast induced AKI16 (0.7)Malaria1 (0.1)Others60 (2.4)KDIGO stage AT AKI diagnosis1944 (79.1)1237 (9.7)3276 (11.2)Mean baseline serum creatinine (µmol/l)104.2 (±70.8)	Neurological comorbidities	, (0.5)
Chronic neurological diseases54 (2.2)Others3 (0.1)Miscellaneous comorbidities41 (1.7)Primary aetiology of AKI1023 (41.7)Sepsis associated AKI1023 (41.7)Prerenal595 (24.2)Cardiorenal syndrome266 (10.8)Dengue175 (7.1)Obstructive uropathy96 (3.9)Drug associated AKI46 (1.9)Hypertensive emergency45 (1.8)Ischaemic acute tubular necrosis42 (1.7)Hepatorenal syndrome31 (1.3)Leptospirosis20 (0.8)Intratubular obstruction19 (0.8)Golomerulonephritis19 (0.8)Contrast induced AKI10.1)Others60 (2.4)KDIGO stage AT AKI diagnosis1944 (79.1)12237 (9.7)3276 (11.2)Mean baseline serum creatinine (µmol/l)104.2 (470.8)	Stroke/Transient ischaemic attack	197 (8.0)
Others3 (0.1)Miscellaneous comorbidities41 (1.7)Primary aetiology of AKI1023 (41.7)Sepsis associated AKI1023 (41.7)Prerenal595 (24.2)Cardiorenal syndrome266 (10.8)Dengue175 (7.1)Obstructive uropathy96 (3.9)Drug associated AKI46 (1.9)Hypertensive emergency45 (1.8)Ischaemic acute tubular necrosis42 (1.7)Hepatorenal syndrome31 (1.3)Leptospirosis20 (0.8)Intratubular obstruction19 (0.8)Gomerulonephritis19 (0.8)Contrast induced AKI16 (0.7)Malaria1 (0.1)Others60 (2.4)KDIGO stage AT AKI diagnosis237 (9.7)12237 (9.7)2237 (9.7)3276 (11.2)Mean baseline serum creatinine (µmol/l)104.2 (±70.8)	Chronic neurological diseases	54 (2.2)
Miscellaneous comorbidities 41 (1.7) Primary aetiology of AKI 1023 (41.7) Sepsis associated AKI 1023 (41.7) Prerenal 595 (24.2) Cardiorenal syndrome 266 (10.8) Dengue 175 (7.1) Obstructive uropathy 96 (3.9) Drug associated AKI 46 (1.9) Hypertensive emergency 45 (1.8) Ischaemic acute tubular necrosis 42 (1.7) Hepatorenal syndrome 31 (1.3) Leptospirosis 20 (0.8) Intratubular obstruction 19 (0.8) Glomerulonephritis 19 (0.8) Contrast induced AKI 16 (0.7) Malaria 1 (0.1) Others 60 (2.4) KDIGO stage AT AKI diagnosis 237 (9.7) 1 237 (9.7) 3 276 (11.2) Mean baseline serum creatinine (µmol/l) 104.2 (±70.8)	Others	3 (0.1)
Primary aetiology of AKISepsis associated AKI1023 (41.7)Prerenal595 (24.2)Cardiorenal syndrome266 (10.8)Dengue175 (7.1)Obstructive uropathy96 (3.9)Drug associated AKI46 (1.9)Hypertensive emergency45 (1.8)Ischaemic acute tubular necrosis42 (1.7)Hepatorenal syndrome31 (1.3)Leptospirosis20 (0.8)Intratubular obstruction19 (0.8)Glomerulonephritis19 (0.8)Contrast induced AKI16 (0.7)Malaria1 (0.1)Others60 (2.4)KDIGO stage AT AKI diagnosis1944 (79.1)2237 (9.7)3276 (11.2)Mean baseline serum creatinine (µmol/l)104.2 (±70.8)	Miscellaneous comorbidities	41 (1.7)
bepsis associated AKI 1023 (41.7) Prerenal 595 (24.2) Cardiorenal syndrome 266 (10.8) Dengue 175 (7.1) Obstructive uropathy 96 (3.9) Drug associated AKI 46 (1.9) Hypertensive emergency 45 (1.8) Ischaemic acute tubular necrosis 42 (1.7) Hepatorenal syndrome 31 (1.3) Leptospirosis 20 (0.8) Intratubular obstruction 19 (0.8) Glomerulonephritis 19 (0.8) Contrast induced AKI 16 (0.7) Malaria 1 (0.1) Others 60 (2.4) KDIGO stage AT AKI diagnosis 1944 (79.1) 1 237 (9.7) 3 276 (11.2) Mean baseline serum creatinine (µmol/l) 104.2 (±70.8)	Primary aetiology of AKI	1022 (41 7)
Cardiorenal syndrome 266 (10.8) Dengue 175 (7.1) Obstructive uropathy 96 (3.9) Drug associated AKI 46 (1.9) Hypertensive emergency 45 (1.8) Ischaemic acute tubular necrosis 42 (1.7) Hepatorenal syndrome 31 (1.3) Leptospirosis 20 (0.8) Intratubular obstruction 19 (0.8) Glomerulonephritis 19 (0.8) Contrast induced AKI 16 (0.7) Malaria 1 (0.1) Others 60 (2.4) KDIGO stage AT AKI diagnosis 1 1 237 (9.7) 3 276 (11.2) Mean baseline serum creatinine (µmol/l) 104.2 (±70.8)	Prerenal	1025 (41.7) 595 (24.2)
Dengue175 (7.1)Obstructive uropathy96 (3.9)Drug associated AKI46 (1.9)Hypertensive emergency45 (1.8)Ischaemic acute tubular necrosis42 (1.7)Hepatorenal syndrome31 (1.3)Leptospirosis20 (0.8)Intratubular obstruction19 (0.8)Glomerulonephritis19 (0.8)Contrast induced AKI16 (0.7)Malaria1 (0.1)Others60 (2.4)KDIGO stage AT AKI diagnosis1944 (79.1)1237 (9.7)3276 (11.2)Mean baseline serum creatinine (µmol/l)104.2 (±70.8)	Cardiorenal syndrome	266 (10.8)
Obstructive uropathy96 (3.9)Drug associated AKI46 (1.9)Hypertensive emergency45 (1.8)Ischaemic acute tubular necrosis42 (1.7)Hepatorenal syndrome31 (1.3)Leptospirosis20 (0.8)Intratubular obstruction19 (0.8)Glomerulonephritis19 (0.8)Contrast induced AKI16 (0.7)Malaria1 (0.1)Others60 (2.4)KDIGO stage AT AKI diagnosis237 (9.7)1237 (9.7)3276 (11.2)Mean baseline serum creatinine (µmol/l)104.2 (±70.8)	Dengue	175 (7.1)
Drug associated AKI46 (1.9)Hypertensive emergency45 (1.8)Ischaemic acute tubular necrosis42 (1.7)Hepatorenal syndrome31 (1.3)Leptospirosis20 (0.8)Intratubular obstruction19 (0.8)Glomerulonephritis19 (0.8)Contrast induced AKI16 (0.7)Malaria1 (0.1)Others60 (2.4)KDIGO stage AT AKI diagnosis1944 (79.1)2237 (9.7)3276 (11.2)Mean baseline serum creatinine (µmol/l)104.2 (±70.8)	Obstructive uropathy	96 (3.9)
Hypertensive emergency45 (1.8)Ischaemic acute tubular necrosis42 (1.7)Hepatorenal syndrome31 (1.3)Leptospirosis20 (0.8)Intratubular obstruction19 (0.8)Glomerulonephritis19 (0.8)Contrast induced AKI16 (0.7)Malaria1 (0.1)Others60 (2.4)KDIGO stage AT AKI diagnosis1944 (79.1)2237 (9.7)3276 (11.2)Mean baseline serum creatinine (µmol/l)104.2 (±70.8)	Drug associated AKI	46 (1.9)
Ischaemic acute tubular necrosis42 (1.7)Hepatorenal syndrome31 (1.3)Leptospirosis20 (0.8)Intratubular obstruction19 (0.8)Glomerulonephritis19 (0.8)Contrast induced AKI16 (0.7)Malaria1 (0.1)Others60 (2.4)KDIGO stage AT AKI diagnosis1944 (79.1)2237 (9.7)3276 (11.2)Mean baseline serum creatinine (µmol/l)104.2 (±70.8)	Hypertensive emergency	45 (1.8)
Hepatorenal syndrome 31 (1.3) Leptospirosis 20 (0.8) Intratubular obstruction 19 (0.8) Glomerulonephritis 19 (0.8) Contrast induced AKI 16 (0.7) Malaria 1 (0.1) Others 60 (2.4) KDIGO stage AT AKI diagnosis 1944 (79.1) 2 237 (9.7) 3 276 (11.2) Mean baseline serum creatinine (µmol/l) 104.2 (±70.8)	Ischaemic acute tubular necrosis	42 (1.7)
Leptosphosis 20 (0.8) Intratubular obstruction 19 (0.8) Glomerulonephritis 19 (0.8) Contrast induced AKI 16 (0.7) Malaria 1 (0.1) Others 60 (2.4) KDIGO stage AT AKI diagnosis 1 1 1944 (79.1) 2 237 (9.7) 3 276 (11.2) Mean baseline serum creatinine (µmol/l) 104.2 (±70.8)	Hepatorenal syndrome	31 (1.3)
Glomerulonephritis 19 (0.8) Contrast induced AKI 16 (0.7) Malaria 1 (0.1) Others 60 (2.4) KDIGO stage AT AKI diagnosis 1944 (79.1) 1 237 (9.7) 3 276 (11.2) Mean baseline serum creatinine (µmol/l) 104.2 (±70.8)	Intratubular obstruction	20 (0.0) 19 (0.8)
Contrast induced AKI 16 (0.7) Malaria 1 (0.1) Others 60 (2.4) KDIGO stage AT AKI diagnosis 1 1 237 (9.7) 3 276 (11.2) Mean baseline serum creatinine (µmol/l) 104.2 (±70.8)	Glomerulonephritis	19 (0.8)
Malaria 1 (0.1) Others 60 (2.4) KDIGO stage AT AKI diagnosis 1 1 1944 (79.1) 2 237 (9.7) 3 276 (11.2) Mean baseline serum creatinine (µmol/l) 104.2 (±70.8)	Contrast induced AKI	16 (0.7)
Others 60 (2.4) KDIGO stage AT AKI diagnosis 1 1 1944 (79.1) 2 237 (9.7) 3 276 (11.2) Mean baseline serum creatinine (µmol/l) 104.2 (±70.8)	Malaria	1 (0.1)
KDIGO stage AT AKI diagnosis 1944 (79.1) 1 237 (9.7) 3 276 (11.2) Mean baseline serum creatinine (µmol/l) 104.2 (±70.8)	Others	60 (2.4)
1 1944 (79.1) 2 237 (9.7) 3 276 (11.2) Mean baseline serum creatinine (μmol/l) 104.2 (±70.8)	KDIGO stage AT AKI diagnosis	
2 237 (9.7) 3 276 (11.2) Mean baseline serum creatinine (μmol/l) 104.2 (±70.8)		1944 (79.1)
Mean baseline serum creatinine (µmol/l) 104.2 (±70.8)	2	237 (9.7) 276 (11 2)
	Mean baseline serum creatinine (μmol/l)	104.2 (±70.8)

Table I: Demography of patients with Acute Kidney Injury (AKI) (N=2 457)

KDIGO- Kidney Disease Improving Global Outcomes

Table II: In-patient course of acute kidney injury

Parameters	Number (%)
Referred to nephrology	
Yes	405 (16.5)
No	2,052 (83.5)
History of ICU admission	
Yes	404 (16.4)
No	2,053 (83.6)
AKI diagnosed in ICU	
Yes	322 (13.1)
No	2,135 (86.9)
Started on dialysis	
Yes	176 (7.2)
No	2,281 (92.8)

ICU-Intensive Care Unit

Table III: Renal replacement therapy results, N = 171, 5 missing

Parameters	No (%)
Where was RRT first started	
ICU	95 (55.6)
Non-ICU	76 (44.4)
Indication for first RRT	
Acidosis	79 (46.2)
Uraemia	54 (31.6)
Electrolyte disturbance	19 (11.1)
Overload	9 (5.3)
Oliguria	9 (5.3)
Paraguat poisoning	1 (0.5)
First RRT mode	
IHD/SLED	147 (86)
CRRT	24 (14)
PD	0 (0)
Mean±SD	
Blood urea at initiation of RRT (mmol/l)	28.1 (±12.1)
Serum creatinine (µmol/l)	548.5 (±368.3)
Bicarbonate (N = 166)	15.4 (±5.0)
Potassium (mmol/l) (N = 170)	4.63 (±1.0)
Lactate mmol/I (N = 69)	4.4 (±4.0)

ICU-Intensive Care Unit; CRRT - Continuous renal replacement therapy; IHD - Intermittent haemodialysis; SLED - Slow low efficiency dialysis; PD - Peritoneal dialysis

Table IV: Matching with National Renal Registry for Malaysians who developed end stage kidney disease (N=1 964) excluding 89 foreigners

Parameter	Number	%	
Matched	38	1.9	
Not matched	1 926	98.1	
Modality			
Haemodialysis	34	89.5	
Peritoneal dialysis	4	10.5	
Outcome			
Alive	32	84.2	
Dead	6	15.8	

Date of study: March 2017

Date of matching: 31 December 2018

Parameters	5		Univariate		Multivariate			
	Number	HR	95% CI	p value	HR	95% CI	p value	
Risk factors				-			-	
Age		1.03	1.02-1.03	<0.001	1.02	1.02-1.03	<0.001	
Ethnicity					_			
Malay	1 283	1			1			
Chinese	579	1.36	1.19-1.56	<0.001	1.07	0.93-1.23	0.355	
Indian	469	0.87	0.74-1.03	0.097	0.88	0.74-1.03	0.114	
Foreigner	109	1.84	1.17-2.89	0.008	3.02	1.91-4.79	<0.001	
Others	16	1.04	0.56-1.95	0.890	0.88	0.47-1.65	0.696	
Diabetes mellitus		-						
No		1			1			
Yes	1144	1.22	1.09-1.36	0.001	1.09	0.96-1.25	0.181	
Hypertension								
No		1			1			
Yes	1 352	1.22	1.09-1.37	0.001	0.84	0.74-0.97	0.018	
Chronic liver disease								
No		1			1			
Yes	90	2.00	1.57-2.54	<0.001	2.13	1.63-2.76	<0.001	
Malignancy								
No		1			1			
Yes	194	2.18	1.84-2.58	<0.001	2.14	1.79-2.55	<0.001	
Chronic kidney disease								
No		1			1			
Yes	434	1.34	1.15-1.57	<0.001	1.02	0.86-1.20	0.818	
Cardiovascular disease								
No		1			1			
Yes	630	1.38	1.21-1.57	<0.001	1.17	1.02-1.35	0.028	
Neurological disease								
No		1			1			
Yes	254	1.73	1.48-2.04	<0.001	1.56	1.33-1.84	<0.001	
Aetiology: Ischaemic ATN								
No		1			1			
Yes	42	0.36	0.18-0.72	0.004	0.35	0.17-0.70	0.003	
Aetiology: Cardio-renal syndrome								
No		1			1			
Yes	266	1.28	1.08-1.52	0.004	1.35	1.11-1.65	0.003	
Aetiology: Sepsis associated AKI								
No		1			1			
Yes	1023	1.34	1.19-1.50	<0.001	1.25	1.10-1.43	0.001	
Aetiology: Hepatorenal syndrome								
No		1			1			
Yes	31	2.08	1.40-3.09	0.001	1.94	1.24-3.04	0.004	
Aetiology: Dengue								
No		1			1			
Yes	175	0.05	0.02-0.13	<0.001	0.13	0.05-0.32	<0.001	
Management risk profiling								
History of ICU admission								
No		1			1			
Yes	404	1.65	1.433-1.89	<0.001	1.67	1.43-1.95	<0.001	
Nephrology referral								
No		1			1			
Yes	405	2.03	1.78-2.32	<0.001	1.48	1.23-1.79	<0.001	
Requirement for RRT								
No		1			1			
Yes	176	2.67	2.25-3.16	<0.001	1.45	1.14-1.85	0.003	

Table V: Univariate and multivariate analysis of risk factors associated with mortality for patients with Acute Kidney Injury from admission till 31st Dec 2018 (N = 2 457)

HR-Hazard Ratio; 95%CI-95% Confidence Intervals; ATN-Acute tubular necrosis, Hazard ratio (HR) for death among hospitalised patients with AKI.

A prospective study of incidence and outcome of acute kidney injury among hospitalised patients in Malaysia (My-AKI)



Fig. 1: Flow diagram.

Nephrology referral (HR 1.48, 95%CI 1.23, 1.79), ICU admission (HR 1.67, 95%CI 1.43, 1.95) and dialysis requirement (HR 1.45, 95%CI 1.14, 1.85]) also predicted death (Table V, Figure 2).

DISCUSSION

This is the first prospective, multicentre study in Malaysia using the KDIGO AKI 2012 criteria to define the incidence,

aetiologies and outcomes of AKI among hospitalised patients. We included an extended follow-up duration up to 22 months.

The baseline creatinine was determined as the lowest creatinine during the hospitalisation as serum creatinine within seven days before hospitalisation was commonly not available. This methodology was adopted from the KDIGO AKI and various other groups.^{26,28,29}



Hospital mortality: 404 out of 2 457 = 16.4%

Population	Number of	Number of	In-hospital	Survival				
·	subjects	subjects deaths (Rate)		30 days	60 days	90 days	1 year	1.5 year
Whole population	2 457	997 (40.6%)	404 (16.4%)	0.78	0.74	0.71	0.63	0.60
With CVS Comorbidities	535	277 (51.8%)	100 (36.1%)	0.74	0.68	0.66	0.55	0.52
Caused by sepsis	1 023	461 (45.1%)	209 (45.3%)	0.75	0.70	0.67	0.59	0.56
Admitted to ICU	404	204 (50.5%)	136 (66.7%)	0.64	0.59	0.57	0.50	0.49

CVS-cardiovascular, ICU-intensive care unit

Fig. 2: Survival curve for all AKI patients from admission till 31st December 2018 (N = 2 457).

All of the participating centres are public hospitals funded by the Ministry of Health Malaysia and are equipped with intensive care units. Four centres are tertiary referral hospitals, and the remaining three centres are district hospitals.

The incidence of hospitalised AKI (7.2%) was comparable to Yang L et al.,28 but lower than other studies in China (11.6%), Japan (11.6%) and United States of America (18.3%).^{29:31} The discrepancies might be due to differences in methodology and population case-mix. The mean age of our cohort (57.8 years) was similar to study by Yang L et al., but relatively younger compared to other reports.

Four out of five patients (81.5%) who developed AKI had at least one comorbidity. There was a high prevalence of diabetes in our study cohort, consistent with the rising prevalence of 17.5% among the general Malaysian population.³²

Malaysia is categorised among upper middle-income countries by the World Bank.³³ The rate of AKI incidence attributed to gastroenteritis was 3%. Gastroenteritis caused 19% of AKI in a series from Malawi³⁴ and 23% of AKI with febrile illness from a recent study in India.³⁵ Only a small proportion of AKI was associated with tropical diseases and pregnancy. Leptospirosis, malaria and snake bite causing AKI was also rare. The initiative from the International Society of Nephrology aspires to eliminate preventable deaths from AKI by 2025.³⁶ All the patients who required dialysis were referred to nephrologists to facilitate transition between different modalities of dialysis such as CRRT, SLED and intermittent HD. Peritoneal dialysis was not utilised to treat AKI patients in any of the participating centres.

The patients who were admitted to the ICU and acquired AKI were usually more ill hence they have higher mortality. Most of those who received CRRT were on inotropic support.

The overall in-hospital mortality was 16.4%, mostly in relation to the cause of AKI and severity of illness. There was also an increased death rate after being discharged home (30.2%) and 1.9% progressed to end-stage kidney failure during an average follow-up of 13.7 months. A single centre study from Singapore reported a mortality rate of 9.4% among AKI patients within six months of post-discharge from hospital for AKI.³⁷ Another study from Canada showed a mortality of 28.0% at one year.³⁸ Therefore, it is important that patients with a history of AKI are followed up long term. Foreigners (n=89, 3.6%) were excluded from follow-up analysis as they were not registered with NRD and NRR.

Besides this, dengue fever is a cause for concern as it is endemic in Malaysia. Dengue as a cause of AKI is unique to the region. Our study showed that dengue patients who developed AKI had five times higher mortality (1.1%) compared to the national reported dengue mortality of 0.21%.³⁹ However, from multivariate analysis, dengue had better outcome compared to other causes of AKI. Factors that contribute to better prognosis of dengue include nationwide active surveillance, adherence to standard protocol and clinical practice guidelines as well as dengue outcome being a key performance indicator for administrators in the Ministry of Health.⁴⁰

The main treatment is assessment of fluid status and timely fluid resuscitation. The condition tends to improve when the proper amount of fluid has been replaced, although in a small percentage, complications can arise, with deterioration to shock syndrome and the patient goes into ICU.

This multicentre study revealed the common causes, population at risk of developing AKI and the predictors of mortality. The incidence of AKI in hospitals and mortality may be reduced by early detection and prompt management of risk factors. Renal replacement therapy escalates the costs and mortality.

The strength of the study includes the large population studied, inclusion of multiple sites and the use of the KDIGO 2012 criteria for AKI.

However, there are limitations to the study. The statistical power of this study might improve with longer duration of follow-up and involvement of more sites especially from East Malaysia. Case-mix from this region might differ from West Malaysia. Apart from this, urine output criteria for diagnosis of AKI were not included, and hospitalised patients who only had a single or no serum creatinine test were excluded. This might underestimate the actual number of AKI.

CONCLUSION

Acute Kidney Injury (AKI) is common in hospitalised patients. It is associated with high in-patient mortality and increased mortality even after discharge. There is a risk of end stage kidney disease (ESKD), and patients need continued surveillance. It is recommended to have a guideline for AKI in Malaysia and to raise awareness so that there is earlier diagnosis and treatment of this serious condition.

ACKNOWLEDGEMENTS

Kuala Lumpur Hospital: Ghazali Ahmad, Schee JP; Tengku Ampuan Rahimah, Klang Hospital: Shahnaz Shah, Tan HE; Tuanku Ja'afar Hospital, Seremban: Lim YL; Serdang Hospital: Goh BL, Aniz Nor Sofia M, Hanani H, Ang KL; Selayang Hospital: Wong HS, Lee FY; Penang Hospital: Teo LK; Seberang Jaya Hospital: Teoh GL, Chan BT. Data from three participating centres were not included as the data were incomplete: Sultanah Bahiyah Hospital, Alor Setar: Ching CH; University Malaya Medical Centre, Kuala Lumpur: Wan Ahmad Hafiz WMA; Raja Perempuan Zainab II Hospital, Kota Bharu: Wan Hasnul Halimi WH

The authors would like to thank the Director General of Health, Ministry of Health Malaysia for permission to publish this paper.

DISCLOSURES

None

REFERENCES

- 1. Suleiman AB, Yahya, S. Acute renal failure in Kuala Lumpur. Med J Malaysia 1981; 36(1): 11-3.
- 2. Suleiman AB, Morad Z, Prasad S. Prospective study of acute renal failure in a general hospital. Med J Malaysia 1987; 42(4): 230-7.
- 3. Chow YW, Lim BB, Hooi LS. Acute renal failure in the same hospital 10 years apart. Med J Malaysia 2007; 62(1): 27-32.
- Tai LL, Lim HC, Mohd Ridhwan MN, Nahla Irtiza I, Nasrudin WIW. Malaysian Registry Intensive Care 2016 Report. Malaysian Registry of Intensive Care; 2017 [cited 2019 Sep 16] p. 1–52. Available from: https://www.crc.gov.my/wpcontent/uploads/documents/report/mric_report_2016.pdf
- Kellum JA, Lameire N, for the KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care 2013; 17(1): 204.
- 6. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative workgroup. Acute renal failure definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the acute dialysis quality initiative (ADQI) group. Crit Care 2004; 8(4): R204-12.
- National Clinical Guideline Centre (UK). Acute Kidney Injury: Prevention, Detection and Management Up to the Point of Renal Replacement Therapy. London: Royal College of Physicians (UK); 2013 [cited 2019 Aug 22]. (National Institute for Health and Clinical Excellence: Guidance). Available from: http://www.ncbi.nlm.nih.gov/books/NBK247665/
- Steward J, Findlay G, Smith N, Kelly K, Mason M. NCEPOD -Acute Kidney Injury: Adding Insult to Injury Report (2009). National Confidential Enquiry into Patient Outcome and Death [cited 2019 Sep 16] pp. 1–100. Available from: https://www.ncepod.org.uk/2009aki.html
- 9. Stevens PE, Tamimi NA, Al-Hasani MK, Mikhail AI, Kearney E, Lapworth R, et al. Non-specialist management of acute renal failure. QJM 2001; 94(10): 533-40.
- 10. Vijayan A, Miller SB. Acute renal failure: prevention and nondialytic therapy. Semin Nephrol 1998; 18(5): 523-32.
- 11. Davidman M, Olson P, Kohen J, Leither T, Kjellstrand C. Iatrogenic renal disease. Arch Intern Med 1991; 151(9): 1809-12.
- Cerdá J, Bagga A, Kher V, Chakravarthi RM. The contrasting characteristics of acute kidney injury in developed and developing countries. Nat Clin Pract Nephrol 2008; 4(3): 138-53.
- Hou SH, Bushinsky DA, Wish JB, Cohen JJ, Harrington JT. Hospital-acquired renal insufficiency: a prospective study. Am J Med 1983; 74(2): 243-8.

- Shusterman N, Strom BL, Murray TG, Morrison G, West SL, Maislin G. Risk factors and outcome of hospital-acquired acute renal failure. Clinical epidemiologic study. Am J Med 1987; 83(1): 65-71.
- Cosentino F, Chaff C, Piedmonte M. Risk factors influencing survival in ICU acute renal failure. Nephrol Dial Transplant 1994; 9(Suppl 4): 179-82.
- Clermont G, Acker CG, Angus DC, Sirio CA, Pinsky MR, Johnson JP. Renal failure in the ICU: comparison of the impact of acute renal failure and end-stage renal disease on ICU outcomes. Kidney Int 2002; 62(3): 986-96.
- 17. Druml W. Long term prognosis of patients with acute renal failure: is intensive care worth it? Intensive Care Med 2005; 31(9): 1145-7.
- Ahlström A, Tallgren M, Peltonen S, Räsänen P, Pettilä V. Survival and quality of life of patients requiring acute renal replacement therapy. Intensive Care Med 2005; 31(9): 1222-8.
- Liaño F, Junco E, Pascual J, Madero R, Verde E. The spectrum of acute renal failure in the intensive care unit compared with that seen in other settings. the madrid acute renal failure study group. Kidney Int Suppl 1998; 66: S16-24.
- 20. Chawla LS, Amdur RL, Amodeo S, Kimmel PL, Palant CE. The severity of acute kidney injury predicts progression to chronic kidney disease. Kidney Int 2011; 79(12): 1361-9.
- 21. Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int 2012; 81(5): 442-8.
- Chawla LS, Eggers PW, Star RA, Kimmel PL. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med 2014; 371(1): 58-66.
- 23. StataCorp. Stata Statistical Software: Release 10. College Station, TX: StataCorp LP 2007.
- 24. Pan H-C, Wu P-C, Wu V-C, et al. A nationwide survey of clinical characteristics, management, and outcomes of acute kidney injury (AKI)-patients with and without preexisting chronic kidney disease have different prognoses. Medicine (Baltimore) 2016; 95(39): e4987.
- 25. Johnson M, Hounkpatin H, Fraser S, Culliford D, Uniacke M, Roderick P. Using a linked database for epidemiology across the primary and secondary care divide: acute kidney injury. BMC Med Inform Decis Mak 2017; 17(1): 106.
- 26. Wonnacott A, Meran S, Amphlett B, Talabani B, Phillips A. Epidemiology and outcomes in community-acquired versus hospital-acquired AKI. Clin J Am Soc Nephrol 2014; 9(6): 1007-14.
- Lewington A, Kanagasundaram S. Renal association clinical practice guidelines on acute kidney injury. Nephron Clin Pract 2011; 118(s1): c349-90.
- Yang L, Xing G, Wang L, Wu Y, Li S, Xu G, et al. Acute kidney injury in China: a cross-sectional survey. Lancet 2015; 386(10002): 1465-71.

- Xu X, Nie S, Liu Z, Chen C, Xu G, Zha Y, et al. Epidemiology and clinical correlates of AKI in Chinese hospitalised adults. Clin J Am Soc Nephrol 2015; 10(9): 1510-8.
- Fujii T, Uchino S, Takinami M, Bellomo R. Validation of the Kidney disease improving global outcomes criteria for AKI and comparison of three criteria in hospitalised patients. Clin J Am Soc Nephrol 2014; 9(5): 848-54.
- Zeng X, McMahon GM, Brunelli SM, Bates DW, Waikar SS. Incidence, outcomes, and comparisons across definitions of AKI in hospitalised individuals. Clin J Am Soc Nephrol 2014; 9(1): 12-20.
- 32. National Health and Morbidity Survey 2015 (NHMS 2015). Vol II: Non-Communicable Disease, Risk Factors & Other Health Problems. Institute For Public Health (IPH) 2015 [cited Oct 2019] p. 315. Available from: http://iku.moh.gov.my/index.php/ research-eng/list-of-research-eng/iku-eng/nhms-eng/nhms-2015.
- 33. World Bank Country and Lending Groups-World Bank Data Help Desk. World Bank Country and Lending Groups,2019 [cited Oct 2019]. Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/906 519-world-bank-country-and-lending-groups.
- 34. Evans RDR, Hemmilä U, Craik A, Mtekateka M, Hamilton F, Kawale Z, et al. Incidence, aetiology and outcome of communityacquired acute kidney injury in medical admissions in Malawi. BMC Nephrol 2017; 18(1): 21.
- 35. Mehta K, Pajai A, Bhurke S, Shirkande A, Bhadade R, D'Souza R. Acute kidney injury of infectious etiology in monsoon season: a prospective study using acute kidney injury network criteria. Indian J Nephrol 2018; 28(2): 143-52.
- 36. Mehta RL, Burdmann EA, Cerdá J, Feehally J, Finkelstein F, García-García G, et al. Recognition and management of acute kidney injury in the international society of nephrology Oby25 global snapshot: a multinational cross-sectional study. Lancet 2016; 387(10032): 2017-25.
- 37. Teo SH, Lee K-G, Koniman R, Tng ARK, Liew ZH, Naing TT, et al. A prospective study of clinical characteristics and outcomes of acute kidney injury in a tertiary care Centre. BMC Nephrol 2019; 20(1): 282.
- Silver SA, Harel Z, McArthur E, Nash DM, Acedillo R, Kitchlu A, et al. Causes of death after a hospitalisation with AKI. J Am Soc Nephrol 2018; 29(3): 1001-10.
- Malaysia Dengue Incidence Rate & Case Fatality for Year 2000-2017. [cited 2019 Sep 24]. Available from: http://idengue.remotesensing.gov.my/idengue/content/statistik. pdf
- 40. Clinical Practice Guidelines. Management of Dengue Infection in Adults. 3rd Edition. Ministry of Health Malaysia 2015 [cited Sep2019]. 7 p. Available from: www.moh.gov.my